Recombinant ErbB2/Her2 (Pertuzumab Biosimilar) antibody

Catalog No. ABIN7200658

This anti-ErbB2/Her2 (Pertuzumab Biosimilar) antibody is a Mouse Monoclonal antibody detecting ErbB2/Her2 (Pertuzumab Biosimilar) in FACS and in vivo. Suitable for Human.

Quick Overview for Recombinant ErbB2/Her2 (Pertuzumab Biosimilar) antibody (ABIN7200658)

Target: ErbB2/Her2 (Pertuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This ErbB2/Her2 (Pertuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details anti-ErbB2/Her2 (Pertuzumab Biosimilar) Antibody

Purpose: Pertuzumab Biosimilar, Human HER2 Monoclonal Antibody

Specificity: The monoclonal antibody pertuzumab biosimilar specifically binds to the human HER2/ErbB-2/c-neu.

Characteristics: Recombinant humanized IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody pertuzumab biosimilar was produced in the pertuzumab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pertuzumab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for ErbB2/Her2 (Pertuzumab Biosimilar)

Target: ErbB2/Her2 (Pertuzumab Biosimilar)

Target Type: Biosimilar

Background: Pertuzumab, a humanized monoclonal antibody, inhibits HER dimerization and is used for the treatment of HER2-positive metastatic breast cancer, in combination with trastuzumab and docetaxel. By binding to HER2, Pertuzumab inhibits the dimerization of HER2 with other HER receptors, resulting in slowed tumor growth.